Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | G6PD | P11413 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660514 | 1.00 | KDM4E (0.64) | KDM4EALDH1A1GAAMAPTLMNA | |
| SCHEMBL1785970 | 0.86 | ALDH1A1 (0.62) | KDM4EALDH1A1GAAMAPTLMNA | |
| SCHEMBL4341886 | 0.84 | MAPK1 (0.67) | KDM4EALDH1A1GAAMAPTLMNA | |
| Hydrochloric Acid SCHEMBL4340576 | 0.82 | MAPK1 (0.64) | KDM4EALDH1A1GAAMAPTLMNA | |
| Hydrochloric Acid SCHEMBL4336588 | 0.82 | MAPK1 (0.64) | KDM4EALDH1A1GAAMAPTLMNA | |
| SCHEMBL4332969 | 0.82 | MAPK1 (0.64) | KDM4EALDH1A1GAAMAPTLMNA | |
| SCHEMBL31533497 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1GAAMAPTLMNA | |
| SCHEMBL27343976 | 0.81 | ALDH1A1 (0.56) | KDM4EALDH1A1GAAMAPTLMNA | |
| Hydrochloric Acid SCHEMBL4340573 | 0.80 | MAPK1 (0.62) | KDM4EALDH1A1GAAMAPTLMNA | |
| SCHEMBL20756707 | 0.79 | KDM4E (0.69) | KDM4EALDH1A1GAAMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140264166-A1 | PHENOXYPYRAZOLE COMPOSITION AND PROCESS FOR THE SOLVENT EXTRACTION OF METALS | CYTEC TECHNOLOGY CORP. (US) | 2014-09-18 | — | — | US | claimed |
| US-20130264519-A1 | Phenoxypyrazole Composition and Process for the Solvent Extraction of Metals | CYTEC TECHNOLOGY CORP. | 2013-10-10 | — | — | US | claimed |
| US-8470052-B2 | Phenoxypyrazole composition and process for the solvent extraction of metals | CYTEC TECHNOLOGY CORP. (US) | 2013-06-25 | — | — | US | claimed |
| EP-1926713-B1 | PROCESS FOR THE SOLVENT EXTRACTION OF METALS | CYTEC TECH CORP (US) | 2013-04-10 | — | — | EP | claimed |
| CN-1626540-A | Iridium compound and organic electroluminescent device using the same | SAMSUNG SDI CO LTD (KR) | 2005-06-15 | — | — | CN | claimed |
| EP-1458379-A1 | HYDROXYPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2004-09-22 | — | — | EP | claimed |
| CN-1517427-A | Compound with red light and organic electroluminescence device using the compound | ����SDI��ʽ���� | 2004-08-04 | — | — | CN | claimed |
| US-20040010027-A1 | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them | PHARMACIA & UPJOHN SPA (IT) | 2004-01-15 | — | — | US | claimed |
| WO-2003051358-A1 | HYDROXYPHENYL-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA SPA (IT) | 2003-06-26 | — | — | WO | claimed |
| US-12258340-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| WO-2024078392-A1 | PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2024-04-18 | — | — | WO | disclosed |
| EP-4330233-A1 | PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY | Chengdu Anticancer Bioscience, Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| CN-117321036-A | phenyl-O-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity | 成都安泰康赛生物科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116473965-A | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-1263743-A1 | HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | disclosed |
| WO-2002032897-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002006276-A1 | BETA3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001034580-A1 | HETEROCYCLE SUBSTITUTED DIPHENYL LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| US-3979141-A | Pressure-sensitive recording system comprising 3'-amino-6' or 7'-(pyrazol-1-yl)fluoran compounds as color precursors | MOORE BUSINESS FORMS, INC. (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258340-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | KDM4E 2927/4885ALDH1A1 2260/4885GAA 170/4885 |
| US-20040010027-A1 | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them | CNKSR1, CSNK1A1, CDK6 | KDM4E 1717/4885ALDH1A1 3793/4885GAA 2828/4885 |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | ADRB3, ADRA1A, ADRB1 | KDM4E 3754/4885ALDH1A1 1413/4885GAA 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.